secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001933414-25-000088
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys Therapeutics Q2 net loss $43.3M; cash $324.9M; pre-NDA meeting set for Q4 2025
--------------------------------------------------------------------------------

- Net loss $43.3M vs $41.0M in Q2 2024; R&D expenses $38.3M, G&A $8.5M.
- Cash, equivalents and investments $324.9M, sufficient to fund operations into 2027.
- Explore-CKD Phase 2 met primary endpoints: 9.25 mmHg systolic BP reduction, 30.51% UACR reduction.
- Pre-NDA meeting with FDA scheduled for Q4 2025; Explore-OSA top-line data expected in 1H 2026.
- Pivotal Launch-HTN and Advance-HTN results published in JAMA and NEJM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000088/0001933414-25-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000088/mlys-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001933414-25-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer